News
CELC
79.52
+0.19%
0.15
Weekly Report: what happened at CELC last week (0914-0918)?
Weekly Report · 5d ago
Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion
Seeking Alpha · 09/18 09:20
Celcuity Initiated at Overweight by JP Morgan
Dow Jones · 09/17 12:12
Celcuity Price Target Announced at $157.00/Share by JP Morgan
Dow Jones · 09/17 12:12
JP Morgan Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $157
Benzinga · 09/17 12:02
Celcuity initiated with an Overweight at JPMorgan
TipRanks · 09/17 09:35
Weekly Report: what happened at CELC last week (0907-0911)?
Weekly Report · 09/14 09:05
Weekly Report: what happened at CELC last week (0831-0904)?
Weekly Report · 09/07 09:04
Most shorted stocks on Wall Street
Seeking Alpha · 09/02 14:28
Mid-cap healthcare stocks ranked by quant ratings after earnings season
Seeking Alpha · 09/01 14:15
Weekly Report: what happened at CELC last week (0824-0828)?
Weekly Report · 08/31 09:05
Kazia Therapeutics: Upcoming Data May Validate Best-In-Class Potential Of Paxalisib
Seeking Alpha · 08/27 12:59
Celcuity Submits SNDA To FDA For REVTORPYK In Advanced Breast Cancer
NASDAQ · 08/26 13:28
Celcuity Files sNDA to Expand REVTORPYK Breast Cancer Use
TipRanks · 08/26 12:57
Celcuity submits Revtorpyk sNDA to the FDA
TipRanks · 08/26 12:40
Celcuity Files Supplemental New Drug Application To FDA For REVTORPYK To Treat Breast Cancer
Benzinga · 08/26 12:31
Weekly Report: what happened at CELC last week (0817-0821)?
Weekly Report · 08/24 09:05
Celcuity Is Maintained at Buy by Guggenheim
Dow Jones · 08/17 13:26
Guggenheim Maintains Buy on Celcuity, Raises Price Target to $175
Benzinga · 08/17 13:16
Celcuity Price Target Maintained With a $177.00/Share by Citizens
Dow Jones · 08/17 13:12
More
Webull provides a variety of real-time CELC stock news. You can receive the latest news about Celcuity Inc through multiple platforms. This information may help you make smarter investment decisions.
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.